Advertisement

Allograft Dysfunction

  • Carol Conrad
  • Nicolaus Schwerk
Reference work entry
Part of the Organ and Tissue Transplantation book series (OTT)

Abstract

Lung transplantation is an established treatment option for children and adolescents suffering from end-stage lung diseases refractory to therapy. The primary aims, to prolong life and to improve quality of life, are reached in most cases. Improvements in surgical techniques and perioperative care have led to a relevant decrease of early mortality after lung transplantation, over the last two decades. Nevertheless, long-term survival remains significantly lower compared to other solid organ transplant outcomes. Chronic lung allograft dysfunction (CLAD) is the leading cause of death in lung transplant recipients after the first year from transplantation. Increasing knowledge of pathophysiological processes and risk factors for CLAD have emerged in recent years and new definitions of CLAD subtypes have been proposed. This chapter provides an overview of our current understanding of different forms of allograft dysfunction, their definition criteria and current treatment approaches.

Keywords

Lung transplantation Allograft dysfunction Acute cellular rejection Antibody-mediated rejection Chronic lung allograft rejection Bronchiolitis obliterans syndrome Azithromycin-responsive allograft dysfunction 

References

  1. Amin R, Subbarao P, Jabar A et al (2010) Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax 65:379–383CrossRefPubMedGoogle Scholar
  2. Andreu G, Achkar A, Couetil J et al (1995) Extracorporeal photochemotherapy treatment for acute lung rejection episode. J Heart Lung Transplant 14:793–796PubMedGoogle Scholar
  3. Angaswamy N, Tiriveedhi V, Sarma NJ et al (2013) Interplay between immune responses to HLA and non-HLA self-antigens in allograft rejection. Hum Immunol 74:1478–1485CrossRefPubMedGoogle Scholar
  4. Appel J, Hartwig M, Davis R et al (2005) Utility of peritransplant and rescue intravenous immunoglobulin and extracorporeal immunoadsorption in lung transplant recipients sensitized to HLA antigens. Hum Immunol 66:378–386CrossRefPubMedGoogle Scholar
  5. Astor T, Weill D, Cool C et al (2005) Pulmonary capillaritis in lung transplant recipients: treatment and effect on allograft function. J Heart Lung Transplant 24:2091–2097CrossRefPubMedGoogle Scholar
  6. Baum C, Reichenspurner H, Deuse T (2013) Bortezomib rescue therapy in a patient with recurrent antibody-mediated rejection after lung transplantation. J Heart Lung Transplant 32:1270–1271CrossRefPubMedGoogle Scholar
  7. Becker Y, Samaniego-Picota M, Sollinger H (2006) The emerging role of rituximab in organ transplantation. Transpl Int 19:621–628CrossRefPubMedGoogle Scholar
  8. Benden C, Speich R, Hofbauer G et al (2008) Extracorporeal photopheresis after lung transplantation: a 10-year single center experience. Transplantation 86:1625–1627CrossRefPubMedGoogle Scholar
  9. Berry G, Burke M, Andersen C et al (2013) Pathology of pulmonary antibody-mediated rejection: 2012 update from the pathology council of the ISHLT. J Heart Lung Transplant 32:14–21CrossRefPubMedGoogle Scholar
  10. Burton C, Iversen M, Carlsen J et al (2009) Acute cellular rejection is a risk factor for bronchiolitis obliterans syndrome independent of post-transplant baseline FEV1. J Heart Lung Transplant 28:888–893CrossRefPubMedGoogle Scholar
  11. Clatworthy M (2011) Targeting B cells and antibody in transplantation. Am J Transplant 11:1359–1367CrossRefPubMedPubMedCentralGoogle Scholar
  12. Colvin R, Smith R (2005) Antibody-mediated organ-allograft rejection. Nat Rev Immunol 5:807–817CrossRefPubMedGoogle Scholar
  13. Cooper J, Billingham M, Egan T et al (1993) A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. International Society for Heart and Lung Transplantation. J Heart Lung Transplant 12:713PubMedGoogle Scholar
  14. Corris P, Ryan V, Small T et al (2015) A randomised controlled trial of azithromycin therapy in bronchiolitis obliterans syndrome (BOS) post lung transplantation. Thorax 70:442–450CrossRefPubMedPubMedCentralGoogle Scholar
  15. Estenne M, Maurer J, Boehler A et al (2002) Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 21:297–310CrossRefPubMedGoogle Scholar
  16. Faro A, Visner G (2004) The use of multiple transbronchial biopsies as the standard approach to evaluate lung allograft rejection. Pediatr Transplantation 8:322–328CrossRefGoogle Scholar
  17. Fehr T, Gaspert A (2012) Antibody-mediated kidney allograft rejection: therapeutic options and their experimental rationale. Transpl Int 25:623–632CrossRefPubMedGoogle Scholar
  18. Girnita AL, McCurry KR, Iacono AT et al (2004) HLA-specific antibodies are associated with high-grade and persistent-recurrent lung allograft acute rejection. J Heart Lung Transplant 23:1135–1141CrossRefPubMedGoogle Scholar
  19. Girnita AL, Duquesnoy R, Yousem SA et al (2005) HLA-specific antibodies are risk factors for lymphocytic bronchiolitis and chronic lung allograft dysfunction. Am J Transplant 5:131–138CrossRefPubMedGoogle Scholar
  20. Goldfarb S, Levvey B, Edwards LB et al (2016) The registry of the International Society for Heart and Lung Transplantation: nineteenth pediatric lung and heart–lung transplantation report – 2016; focus theme: primary diagnostic indications for transplant. J Heart Lung Transplant 35:1196–1205CrossRefPubMedGoogle Scholar
  21. Hachem RR, Yusen RD, Meyers BF et al (2010) Anti-human leukocyte antigen antibodies and preemptive antibody-directed therapy after lung transplantation. J Heart Lung Transplant 29:973–980CrossRefPubMedPubMedCentralGoogle Scholar
  22. Hopkins P, Aboyoun C, Chhajed P et al (2002) Prospective analysis of 1,235 transbronchial lung biopsies in lung transplant recipients. J Heart Lung Transplant 21:1062–1067CrossRefPubMedGoogle Scholar
  23. Jaramillo A, Smith C, Maruyama T et al (2003) Anti-HLA class I antibody binding to airway epithelial cells induces production of fibrogenic growth factors and apoptotic cell death: a possible mechanism for bronchiolitis obliterans syndrome. Hum Immunol 64:521–529CrossRefPubMedGoogle Scholar
  24. Jordan S, Vo A, Toyoda M et al (2005) Post-transplant therapy with high dose intravenous gammaglobulin: applications to treatment of antibody-mediated rejection. Pediatr Transplant 9:155–161CrossRefPubMedGoogle Scholar
  25. Jordan S, Toyoda M, Vo A (2011) Regulation of immunity and inflammation by intravenous immunoglobulin: relevance to solid organ transplantation. Expert Rev Clin Immunol 7:341–348CrossRefPubMedGoogle Scholar
  26. Kapila A, Baz M, Valentine V et al (2015) Reliability of diagnostic criteria for bronchiolitis obliterans syndrome after lung transplantation: a survey. J Heart Lung Transplant 34:65–74CrossRefPubMedGoogle Scholar
  27. Kingah PL, Muma G, Soubani A (2014) Azithromycin improves lung function in patients with post lung transplant bronchiolitis obliterans syndrome: a meta-analysis. Clin Transpl 28:906–910CrossRefGoogle Scholar
  28. Kuehnel M, Maegel L, Vogel-Claussen J et al (2017) Airway remodeling in the transplanted lung. Cell Tissue Res 367:663–675CrossRefPubMedGoogle Scholar
  29. Marques M, Schwartz J (2011) Update on extracorporeal photopheresis in heart and lung transplantation. J Clin Apheresis 26:146–151CrossRefPubMedGoogle Scholar
  30. Meyer K, Raghu G, Verleden G et al (2014) An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome. Eur Respir J 44:1479CrossRefPubMedGoogle Scholar
  31. Morrell M, Pilewski J, Gries C et al (2014) De novo donor-specific HLA antibodies are associated with early and high-grade bronchiolitis obliterans syndrome and death after lung transplantation. J Heart Lung Transplant 33:1288–1294CrossRefPubMedGoogle Scholar
  32. Palmer SM, Davis RD, Hadjiliadis D et al (2002) Development of an antibody specific to major histocompatibility antigens detectable by flow cytometry after lung transplant is associated with bronchiolitis obliterans syndrome. Transplantation 74:799–804CrossRefPubMedGoogle Scholar
  33. Rook A, Cohen J (1993) Therapeutic applications of photopheresis. Derm Clin 11:339–347CrossRefGoogle Scholar
  34. Saini D, Angaswamy N, Tiriveedhi V et al (2010) Synergistic effect of antibodies to human leukocyte antigens and defensins in pathogenesis of bronchiolitis obliterans syndrome after human lung transplantation. J Heart Lung Transplant 29:1330–1336CrossRefPubMedPubMedCentralGoogle Scholar
  35. Sengsayadeth S, Srivastava S, Jagasia M et al (2012) Time to explore preventive and novel therapies for Bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 18:1479–1487CrossRefPubMedGoogle Scholar
  36. Singh N, Pirsch J, Samaniego M (2009) Antibody-mediated rejection: treatment alternatives and outcomes. Transplant Rev (Orlando) 23:34–46CrossRefGoogle Scholar
  37. Sivakumar P, Ntolios P, Jenkins G et al (2012) Into the matrix: targeting fibroblasts in pulmonary fibrosis. Curr Opin Pulm Med 18:462–469CrossRefPubMedGoogle Scholar
  38. Snyder L, Palmer S (2006) Immune mechanisms of lung allograft rejection. Semin Respir Crit Care Med 27:534–543CrossRefPubMedGoogle Scholar
  39. Snyder L, Gray A, Reynolds J et al (2014) Antibody desensitization therapy in highly sensitized lung transplant candidates. Am J Transplant 14:849–856CrossRefPubMedPubMedCentralGoogle Scholar
  40. Stewart S, Fishbein M, Snell F et al (2007) Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant 26:1229–1241CrossRefPubMedGoogle Scholar
  41. Szczepiorkowski Z, Bandarenko N, Kim H et al (2007) Guidelines on the use of therapeutic apheresis in clinical practice: evidence-based approach from the Apheresis applications Committee of the American Society Apheresis. J Clin Apher 14:106–175CrossRefGoogle Scholar
  42. Trulock EP, Christie JD, Edwards LB et al (2007) Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult lung and heart-lung transplantation report 2007. J Heart Lung Transplant 26:782–795CrossRefPubMedGoogle Scholar
  43. Verleden G, Vos R, De Vleeschauwer S et al (2009) Obliterative bronchiolitis following lung transplantation: from old to new concepts? Transpl in 22:771Google Scholar
  44. Verleden G, Vos R, Verleden S et al (2011) Survival determinants in lung transplant patients with chronic allograft dysfunction. Transplantation 92:703–708CrossRefPubMedGoogle Scholar
  45. Verleden S, Vos R, Vandermeulen E et al (2013) Involvement of interleukin-17 during lymphocytic bronchiolitis in lung transplant patients. J Heart Lung Transplant 32:447–453CrossRefPubMedGoogle Scholar
  46. Verleden G, Raghu G, Meyer K et al (2014) A new classification system for chronic lung allograft dysfunction. J Heart Lung Transplant 33:127CrossRefPubMedGoogle Scholar
  47. Verleden S, Ruttens D, Vandermeulen E et al (2015a) Restrictive chronic lung allograft dysfunction: where are we now? J Heart Lung Transplant 34:625–630CrossRefPubMedGoogle Scholar
  48. Verleden G, Vos R, Vanaudenaerde B et al (2015b) Current views on chronic rejection after lung transplantation. Transpl Int 28:1131–1139CrossRefPubMedGoogle Scholar
  49. Vo A, Petrozzino J, Yeung K et al (2013) Efficacy, outcomes, and cost effectiveness of desensitization using IVIG and rituximab. Transplantation 95:852–858CrossRefPubMedGoogle Scholar
  50. Vos R, Vanaudenaerde B, Verleden S et al (2011) A randomized controlled trial of azithromycin to prevent chronic rejection after lung transplantation. Eur Respir J 37(1):164–172CrossRefPubMedGoogle Scholar
  51. Vos R, Vanaudenaerde B, Verleden S et al (2012) Anti-inflammatory and immunomodulatory properties of azithromycin involved in treatment and prevention of chronic lung allograft rejection. Transplantation 94:101–109CrossRefPubMedGoogle Scholar
  52. Vos R, Verleden S, Ruttens D et al (2013) Pirfenidone: a potential new therapy for restrictive allograft syndrome? Am J Transplant 13:3035–3040CrossRefPubMedGoogle Scholar
  53. Vos R, Vereleden S, Verleden G (2015) Chronic lung allograft dysfunction: evolving practice. Curr Opin Organ Transplant 20:483–91Google Scholar
  54. Welsh CH, Wang TS, Lyu DM et al (2015) An international ISHLT/ATS/ERS clinical practice guideline: summary for clinicians. Bronchiolitis obliterans syndrome complicating lung transplantation. Revis Ann Am Thorac Soc 12:118–119CrossRefGoogle Scholar
  55. Wong J, Westall G, Snell F (2015) Bronchoscopic procedures and lung biopsies in Pediatric lung transplant recipients. Pediatr Pulmonol 50:1406–1419CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Stanford University School of MedicineStanfordUSA
  2. 2.Klinik für Pädiatrische Pneumologie, Allergologie und NeonatologieMedizinische Hochschule HannoverHannoverGermany

Section editors and affiliations

  • Samuel B Goldfarb
    • 1
  1. 1.The Children's Hospital of PhiladelphiaPhiladelphiaUSA

Personalised recommendations